Anna N. Kirienko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna N. Kirienko has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Irina S. Martynkevich
Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya ul., Saint Petersburg, Russian Federation, 191024
5 shared publications - Daria V. Kustova
Russian Research Institute of Hematology and Transfusiology
4 shared publications - Ekaterina V. Motyko
Russian Research Institute of Hematology and Transfusiology
4 shared publications - Igor A. Tikhonovich
All-Russia Research Institute for Agricultural Microbiology, Podbelskogo hwy, 3, Pushkin, St. Petersburg 196608, Russia
3 shared publications - Irina Viktorovna Leppyanen
All-Russia Research Institute for Agricultural Microbiology
3 shared publications - Anna B. Kitaeva
Laboratory of Molecular and Cell Biology, All-Russia Research Institute for Agricultural Microbiology, Saint Petersburg 196608, Russia
2 shared publications
Latest Publications
- Open Access
- 13 November 2025
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 106 (6) , 898-908
Molecular genetic characteristics and pathogenetic mechanisms of mantle cell lymphoma: a cohort study
BACKGROUND: In addition to the characteristic t(11;14) translocation, the genome of mantle cell lymphoma is distinguished by numerous secondary chromosomal aberrations and molecular genetic alterations. AIM: This study aimed to assess the mutational profile of mantle cell lymphoma, identify the most frequent genetic aberrations, and determine their impact on overall survival. METHODS: Twenty-four patients with classical stage III–IV mantle cell lymphoma were included. All patients underwent conventional cytogenetic analysis, fluorescence in situ hybridization, and next-generation sequencing. Karyotypes were interpreted in accordance with the International System for Human Cytogenomic Nomenclature (ISCN). Moreover, survival functions were estimated using the Kaplan–Meier method with the log-rank test. The relationship between survival time and independent variables was evaluated using univariate and multivariate Cox regression analyses. RESULTS: Conventional cytogenetic analysis determined a normal karyotype in 19 (79.2%) patients. The t(11;14) translocation was detected in three patients, 17p deletion in two (8%), and a complex karyotype in two (8%). Fluorescence in situ hybridization analysis identified t(11;14) translocation in 16 (67%) patients, TP53/17p13 deletion in 4 (17%), and MYC/8q24 rearrangement in 3 (12.5%). TP53/17p13 deletion induced an independent negative effect on overall survival (p = 0.020). NGS revealed the most frequent mutations in ATM (36%), RYR1 (27%), BCR (27%), and KMT2D (23%) genes. Significant associations were observed between FAT1 and BCR (p = 0.013), MGA and KMT2D (p = 0.024), and DNMT3A and KMT2D (p = 0.043) mutations. Among the detected variants, the ATM mutation predicted poor overall survival; however, its statistical significance was lost after adjusting for TP53/17p13 deletion (p = 0.099). CONCLUSION: Analysis of the mutational profile revealed the most frequent aberrations—mutations in ATM, BCR, and KMT2D genes—in mantle cell lymphoma, which potentially contribute to the tumor’s pathogenesis.
- 13 November 2025
- Published by ECO-Vector LLC (Publications) in Kazan medical journal
- Vol. 106 (6) , 898-908
Open AccessMolecular genetic characteristics and pathogenetic mechanisms of mantle cell lymphoma: a cohort study
BACKGROUND: In addition to the characteristic t(11;14) translocation, the genome of mantle cell lymphoma is distinguished by numerous secondary chromosomal aberrations and molecular genetic alterations. AIM: This study aimed to assess the mutational profile of mantle cell lymphoma, identify the most frequent genetic aberrations, and determine their impact on overall survival. METHODS: Twenty-four patients with classical stage III–IV mantle cell lymphoma were included. All patients underwent conventional cytogenetic analysis, fluorescence in situ hybridization, and next-generation sequencing. Karyotypes were interpreted in accordance with the International System for Human Cytogenomic Nomenclature (ISCN). Moreover, survival functions were estimated using the Kaplan–Meier method with the log-rank test. The relationship between survival time and independent variables was evaluated using univariate and multivariate Cox regression analyses. RESULTS: Conventional cytogenetic analysis determined a normal karyotype in 19 (79.2%) patients. The t(11;14) translocation was detected in three patients, 17p deletion in two (8%), and a complex karyotype in two (8%). Fluorescence in situ hybridization analysis identified t(11;14) translocation in 16 (67%) patients, TP53/17p13 deletion in 4 (17%), and MYC/8q24 rearrangement in 3 (12.5%). TP53/17p13 deletion induced an independent negative effect on overall survival (p = 0.020). NGS revealed the most frequent mutations in ATM (36%), RYR1 (27%), BCR (27%), and KMT2D (23%) genes. Significant associations were observed between FAT1 and BCR (p = 0.013), MGA and KMT2D (p = 0.024), and DNMT3A and KMT2D (p = 0.043) mutations. Among the detected variants, the ATM mutation predicted poor overall survival; however, its statistical significance was lost after adjusting for TP53/17p13 deletion (p = 0.099). CONCLUSION: Analysis of the mutational profile revealed the most frequent aberrations—mutations in ATM, BCR, and KMT2D genes—in mantle cell lymphoma, which potentially contribute to the tumor’s pathogenesis.
- Open Access
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 315-325
DNA Methylation Genes in Multiple Myeloma: What We Already Know and How It Can Be Used?
BACKGROUND. The last 20 years have seen a substantial evolution of diagnostic methods and innovation approaches to analyzing genome and transcriptome of tumor cells. Underresearched, however, is the value of aberrant patterns of DNA methylation or methylation-modifying genes in the pathogenesis of multiple myeloma (MM) development and in the mechanisms of tumor progression. Mutation detection by next-generation sequencing (NGS) in disease relapse- and/or drug resistance-associated genes provides the basis for identifying novel targets for drug therapy. AIM. To analyze the molecular genetic landscape and prognostic value of NGS detected mutations in the genes of MM patients. MATERIALS & METHODS. This prospective study enrolls 45 MM patients treated at the Russian Research Institute of Hematology and Transfusiology (Saint Petersburg) from 2011 to the present. The median age of patients was 60 years (range 38–81 years). All patients received mutation screening using a NGS panel with 118 genes. The cells of bone marrow aspirate were subjected to the analysis. A comprehensive study of genetic status included also the standard karyotyping and FISH analysis. RESULTS. Somatic mutations in DNA methylation regulatory genes DNMT3A and TET2 had no significant impact either on objective response or long-term survival rates. However, in case of somatic mutations detected in gene NOTCH1 or ATM, the 3-year progression-free survival was 27.3 % (95% confidence interval [95% CI] 8.0–83.5 %) vs. 59.0 % (95% CI 42.3–82.9 %) without these mutations, the 3-year overall survival was 64 % (95% CI 42.7–96.4 %) and 95% (95% CI 87–100 %), respectively. CONCLUSION. Mutation status of DNA methylation genes has no significant impact either on antitumor response or on long-term survival rates in MM patients. However, genuine potential of of DNA methylation patterns and DNA methylation-modifying genes has not yet been evaluated. Further studies need to be conducted in this field to stratify the risks and to improve the treatment strategy. DNA methylation-modulating agents may eventually join the arsenal of therapeutic options for MM.
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 315-325
Open AccessDNA Methylation Genes in Multiple Myeloma: What We Already Know and How It Can Be Used?
BACKGROUND. The last 20 years have seen a substantial evolution of diagnostic methods and innovation approaches to analyzing genome and transcriptome of tumor cells. Underresearched, however, is the value of aberrant patterns of DNA methylation or methylation-modifying genes in the pathogenesis of multiple myeloma (MM) development and in the mechanisms of tumor progression. Mutation detection by next-generation sequencing (NGS) in disease relapse- and/or drug resistance-associated genes provides the basis for identifying novel targets for drug therapy. AIM. To analyze the molecular genetic landscape and prognostic value of NGS detected mutations in the genes of MM patients. MATERIALS & METHODS. This prospective study enrolls 45 MM patients treated at the Russian Research Institute of Hematology and Transfusiology (Saint Petersburg) from 2011 to the present. The median age of patients was 60 years (range 38–81 years). All patients received mutation screening using a NGS panel with 118 genes. The cells of bone marrow aspirate were subjected to the analysis. A comprehensive study of genetic status included also the standard karyotyping and FISH analysis. RESULTS. Somatic mutations in DNA methylation regulatory genes DNMT3A and TET2 had no significant impact either on objective response or long-term survival rates. However, in case of somatic mutations detected in gene NOTCH1 or ATM, the 3-year progression-free survival was 27.3 % (95% confidence interval [95% CI] 8.0–83.5 %) vs. 59.0 % (95% CI 42.3–82.9 %) without these mutations, the 3-year overall survival was 64 % (95% CI 42.7–96.4 %) and 95% (95% CI 87–100 %), respectively. CONCLUSION. Mutation status of DNA methylation genes has no significant impact either on antitumor response or on long-term survival rates in MM patients. However, genuine potential of of DNA methylation patterns and DNA methylation-modifying genes has not yet been evaluated. Further studies need to be conducted in this field to stratify the risks and to improve the treatment strategy. DNA methylation-modulating agents may eventually join the arsenal of therapeutic options for MM.
- Open Access
- 27 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6236
Expression of WNT Family Genes in Mesenchymal Stromal Cells of the Hematopoietic Niche in Patients with Different Responses to Multiple Myeloma Treatment
Mesenchymal stromal cells of the tumor microenvironment (TME) play a significant role in the progression of multiple myeloma (MM). The cells of the TME demonstrate resistance to treatment, thereby creating a favorable environment for disease relapse. The status of the TME during remission is poorly understood. An association between treatment response and TME status (including signaling pathways) has been suggested. One of the key players in the establishment of the MM TME is WNT signaling. In this study, we evaluated the expression of WNT family proteins in the TME and MM cells to assess their potential as TME markers and predictors of treatment response. A bioinformatic analysis of normal and malignant plasma cells, combined with an analysis of published data, revealed the following differentially expressed WNT genes: WNT5A, WNT10B, CTNNB1, and WNT3A. Immunohistochemical staining with the antibodies against the proteins encoded by the genes was conducted on trephine biopsy samples of bone marrow from healthy donors and patients with different responses to therapy. A quantitative analysis of the immunohistochemical data revealed differences in the amounts of WNT3A, WNT5A, WNT10B, and β-catenin proteins in the bone marrow before treatment depending on the subsequent responses of the patients to therapy. Multiplex fluorescent immunohistochemical staining with tyramide signal amplification revealed that WNT3A was predominantly present in mesenchymal stromal cells, whereas WNT5A and WNT10B were primarily observed in plasma cells. β-catenin was detected in both cell types. We analyzed the mRNA levels of the WNT gene family and CTNNB1 in MSC cultures from healthy donors and patients using qPCR. These genes were differentially expressed in MSC cultures derived from patients and healthy donors, as well as between patients grouped according to their response to therapy. Therefore, WNT proteins and β-catenin can be considered potential markers to assess the state of the tumor niche.
- 27 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6236
Open AccessExpression of WNT Family Genes in Mesenchymal Stromal Cells of the Hematopoietic Niche in Patients with Different Responses to Multiple Myeloma Treatment
Mesenchymal stromal cells of the tumor microenvironment (TME) play a significant role in the progression of multiple myeloma (MM). The cells of the TME demonstrate resistance to treatment, thereby creating a favorable environment for disease relapse. The status of the TME during remission is poorly understood. An association between treatment response and TME status (including signaling pathways) has been suggested. One of the key players in the establishment of the MM TME is WNT signaling. In this study, we evaluated the expression of WNT family proteins in the TME and MM cells to assess their potential as TME markers and predictors of treatment response. A bioinformatic analysis of normal and malignant plasma cells, combined with an analysis of published data, revealed the following differentially expressed WNT genes: WNT5A, WNT10B, CTNNB1, and WNT3A. Immunohistochemical staining with the antibodies against the proteins encoded by the genes was conducted on trephine biopsy samples of bone marrow from healthy donors and patients with different responses to therapy. A quantitative analysis of the immunohistochemical data revealed differences in the amounts of WNT3A, WNT5A, WNT10B, and β-catenin proteins in the bone marrow before treatment depending on the subsequent responses of the patients to therapy. Multiplex fluorescent immunohistochemical staining with tyramide signal amplification revealed that WNT3A was predominantly present in mesenchymal stromal cells, whereas WNT5A and WNT10B were primarily observed in plasma cells. β-catenin was detected in both cell types. We analyzed the mRNA levels of the WNT gene family and CTNNB1 in MSC cultures from healthy donors and patients using qPCR. These genes were differentially expressed in MSC cultures derived from patients and healthy donors, as well as between patients grouped according to their response to therapy. Therefore, WNT proteins and β-catenin can be considered potential markers to assess the state of the tumor niche.
- Open Access
- 23 March 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (1) , 80-87
NGS analysis of the mutational profile of patients with Ph-negative myeloproliferative neoplasms
Introduction. The identification of driver mutations in the JAK2, CALR, and MPL genes is a gold standard approach in the molecular diagnosis of patients with Ph-negative myeloproliferative neoplasms (Ph-MPNs). However, such patients are characterized by a heterogenous genomic landscape. Standard molecular genetic methods cannot be used to identify most somatic mutations, thus failing to provide a comprehensive understanding of the course and prognosis of Ph-MPNs and to confirm the clonality of the disease in patients with triple-negative status. The next generation sequencing (NGS) technology allows simultaneous analysis of an extensive panel of genes and identification of both pathogenic and driver mutations.Aim. To evaluate the possibility of using NGS to study the mutational status of patients with Ph-negative MPNs and to analyze the effect of identified pathogenic mutations on patient survival.Materials and methods. The study included 83 patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis aged from 19 to 85 years (the median onset age of 51 years). For all patients, sequencing was performed using a myeloid panel of 118 genes with an average reading depth of 1000x on MiSeq (Illumina, USA). The clinical significance of the mutations was determined using the COSMIC and Franklin databases. The survival rate was analyzed using the Kaplan–Meyer method followed by assessment of statistical significance using the Cox-Mantel test in the GraphPad Prism 8 environment.Results. Pathogenic mutations in 23 genes were detected in 39 (46%) patients out of the total cohort of patients. The most frequent mutations were detected in the ASXL1 gene in 25% of patients, which reduced event-free survival by 50.3% (Me = 7.83 years vs 15.75 years). The pathogenic mutations identified in other genes combined with mutations in driver genes also decreased event-free survival compared to patients with isolated driver mutations. Two or more pathogenic mutations significantly reduced event-free survival compared to patients with only one pathogenic mutation. The NGS method was also capable of identifying pathogenic mutations in 8 out of 10 triple-negative patients studied, thus confirming the clonality of the disease.Conclusions. The next-generation sequencing (NGS) method using a panel of 118 genes is an effective tool in identifying predictively significant mutations important for selecting the most effective personalized therapy to achieve hematologic response.
- 23 March 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (1) , 80-87
Open AccessNGS analysis of the mutational profile of patients with Ph-negative myeloproliferative neoplasms
Introduction. The identification of driver mutations in the JAK2, CALR, and MPL genes is a gold standard approach in the molecular diagnosis of patients with Ph-negative myeloproliferative neoplasms (Ph-MPNs). However, such patients are characterized by a heterogenous genomic landscape. Standard molecular genetic methods cannot be used to identify most somatic mutations, thus failing to provide a comprehensive understanding of the course and prognosis of Ph-MPNs and to confirm the clonality of the disease in patients with triple-negative status. The next generation sequencing (NGS) technology allows simultaneous analysis of an extensive panel of genes and identification of both pathogenic and driver mutations.Aim. To evaluate the possibility of using NGS to study the mutational status of patients with Ph-negative MPNs and to analyze the effect of identified pathogenic mutations on patient survival.Materials and methods. The study included 83 patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis aged from 19 to 85 years (the median onset age of 51 years). For all patients, sequencing was performed using a myeloid panel of 118 genes with an average reading depth of 1000x on MiSeq (Illumina, USA). The clinical significance of the mutations was determined using the COSMIC and Franklin databases. The survival rate was analyzed using the Kaplan–Meyer method followed by assessment of statistical significance using the Cox-Mantel test in the GraphPad Prism 8 environment.Results. Pathogenic mutations in 23 genes were detected in 39 (46%) patients out of the total cohort of patients. The most frequent mutations were detected in the ASXL1 gene in 25% of patients, which reduced event-free survival by 50.3% (Me = 7.83 years vs 15.75 years). The pathogenic mutations identified in other genes combined with mutations in driver genes also decreased event-free survival compared to patients with isolated driver mutations. Two or more pathogenic mutations significantly reduced event-free survival compared to patients with only one pathogenic mutation. The NGS method was also capable of identifying pathogenic mutations in 8 out of 10 triple-negative patients studied, thus confirming the clonality of the disease.Conclusions. The next-generation sequencing (NGS) method using a panel of 118 genes is an effective tool in identifying predictively significant mutations important for selecting the most effective personalized therapy to achieve hematologic response.
- Open Access
- 1 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 45-60
Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase domain are one of the most common mechanisms for the development of resistance to tyrosine kinase inhibitors.Aim. To conduct a retrospective analysis of the BCR::ABL kinase domain mutational profile in patients with CML observed at the Russian Research Institute of Hematology and Transfusiology from 2012 to 2023. To assess the impact of mutations type and number on the rate of achieving a major molecular response (MMR). To study the risk of MMR loss depending on the therapy line and existing mutational status.Materials and methods. 1831 patients with CML were examined at different times. The mutational status of the BCR::ABL kinase domain was analyzed by direct Sanger sequencing. A standard cytogenetic study was carried out using GTG banding technology with the analysis of at least 20 metaphase plates.Results. Mutations in the BCR::ABL kinase domain were identified in 27.6 % of the total studied patients. The most common mutation, 6.3 % in the overall group or 22.7 % among patients with mutations, was the T315I mutation. Additional chromosomal aberrations (ACAs) were detected in Ph-positive cells in 20.5 % of patients, in Ph-negative clones in 3.9 % of cases (p = 0.0001). The frequency of ACAs detection did not statistically significantly differ (p = 0.25) between patients with BCR::ABL mutations (23.5 %) and with a negative mutation status (17.7 %), and the presence of mutations in the kinase domain did not correlate with ACAs in Ph-positive clones (p = 0.73). However, the frequency of T315I mutation detection in Ph-positive cells had significant differences: 40.9 % in combination with ACAs and 21 % without ACAs (p = 0.032). Patients with the T315I mutation had significantly worse MMR than patients with mutations in other BCR::ABL regions (p = 0.04) and patients without mutations (p = 0.02). The probability of MMR achieving did not differ significantly between patients with different numbers of BCR::ABL mutations (p = 0.14). Loss of MMR occurred more often in patients with mutations (p = 0.04) and not depend on the line of therapy (p = 0.03).Conclusion. For complete monitoring and optimal choice of therapy, CML patients require not only monitoring of BCR::ABL relative expression level, but also standard cytogenetic and analysis of the mutational status.
- 1 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 45-60
Open AccessRetrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia
Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase domain are one of the most common mechanisms for the development of resistance to tyrosine kinase inhibitors.Aim. To conduct a retrospective analysis of the BCR::ABL kinase domain mutational profile in patients with CML observed at the Russian Research Institute of Hematology and Transfusiology from 2012 to 2023. To assess the impact of mutations type and number on the rate of achieving a major molecular response (MMR). To study the risk of MMR loss depending on the therapy line and existing mutational status.Materials and methods. 1831 patients with CML were examined at different times. The mutational status of the BCR::ABL kinase domain was analyzed by direct Sanger sequencing. A standard cytogenetic study was carried out using GTG banding technology with the analysis of at least 20 metaphase plates.Results. Mutations in the BCR::ABL kinase domain were identified in 27.6 % of the total studied patients. The most common mutation, 6.3 % in the overall group or 22.7 % among patients with mutations, was the T315I mutation. Additional chromosomal aberrations (ACAs) were detected in Ph-positive cells in 20.5 % of patients, in Ph-negative clones in 3.9 % of cases (p = 0.0001). The frequency of ACAs detection did not statistically significantly differ (p = 0.25) between patients with BCR::ABL mutations (23.5 %) and with a negative mutation status (17.7 %), and the presence of mutations in the kinase domain did not correlate with ACAs in Ph-positive clones (p = 0.73). However, the frequency of T315I mutation detection in Ph-positive cells had significant differences: 40.9 % in combination with ACAs and 21 % without ACAs (p = 0.032). Patients with the T315I mutation had significantly worse MMR than patients with mutations in other BCR::ABL regions (p = 0.04) and patients without mutations (p = 0.02). The probability of MMR achieving did not differ significantly between patients with different numbers of BCR::ABL mutations (p = 0.14). Loss of MMR occurred more often in patients with mutations (p = 0.04) and not depend on the line of therapy (p = 0.03).Conclusion. For complete monitoring and optimal choice of therapy, CML patients require not only monitoring of BCR::ABL relative expression level, but also standard cytogenetic and analysis of the mutational status.
- 12 November 2021
- Published by Saint Petersburg State University in Biological Communications
- Vol. 66 (3) , 181–197
Transcriptomic analysis of sym28 and sym29 supernodulating mutants of pea (Pisum sativum L.) under complex inoculation with beneficial microorganisms
The garden pea (Pisum sativum L.), like most members of Fabaceae family, is capable of forming symbioses with beneficial soil microorganisms such as nodule bacteria (rhizobia), arbuscular mycorrhizal (AM) fungi and plant growth promoting bacteria (PGPB). The autoregulation of nodulation (AON) system is known to play an important role in controlling both the number of nodules and the level of root colonization by AM via root-to-shoot signaling mediated by CLAVATA/ESR-related (CLE) peptides and their receptors. In the pea, mutations in genes Sym28 (CLV2-like) and Sym29 (CLV1-like), which encode receptors for CLE peptides, lead to the supernodulation phenotype, i.e., excessive nodule formation. The aim of the present study was to analyze the response of pea cv. ‘Frisson’ (wild type) and mutants P64 (sym28) and P88 (sym29) to complex inoculation with rhizobia, AM fungi and PGPB, with regard to biomass accumulation, yield and transcriptomic alterations. The plants were grown in quartz sand for 2 and 4 weeks after inoculation with either rhizobia (Rh) or complex inoculation with Rh + AM, Rh + PGPB, and Rh+AM+PGPB, and the biomass and yield were assessed. Transcriptome sequencing of whole shoots and roots was performed using a modified RNAseq protocol named MACE (Massive Analysis of cDNA Ends). In the experimental conditions, P88 (sym29) plants demonstrated the best biomass accumulation and yield, as compared to the wild type and P64 (sym28) plants, whereas P64 (sym28) had the lowest rate of biomass and seed yield. The transcriptome analysis showed that both supernodulating mutants more actively responded to biotic and abiotic factors than the wild-type plants and demonstrated increased expression of genes characteristic to late stages of nodule development. The roots of P64 (sym28) plants responded to AM+Rh treatment with upregulation of genes encoding plastid proteins, which can be connected with the activation of carotenoid biosynthesis (namely, the non-mevalonate pathway that takes place in root plastids). The more active response to symbionts in P88 (sym29) plants, as compared to cv. ‘Frisson’, was associated with counterregulation of transcripts involved in chloroplast functioning and development in leaves, which accompanies successful plant development in symbiotic conditions. Finally, the effect of retardation of plant aging upon mycorrhization on a transcriptomic level was recorded for cv. ‘Frisson’ but not for P64 (sym28) and P88 (sym29) mutants, which points towards its possible connection with the AON system. The results of this work link the plant’s autoregulation with the responsiveness to inoculation with beneficial soil microorganisms. RNAseq, transcriptomics, arbuscular mycorrhiza, nodule bacteria, complex inoculation, autoregulation of nodulation, garden pea
- 12 November 2021
- Published by Saint Petersburg State University in Biological Communications
- Vol. 66 (3) , 181–197
Transcriptomic analysis of sym28 and sym29 supernodulating mutants of pea (Pisum sativum L.) under complex inoculation with beneficial microorganisms
The garden pea (Pisum sativum L.), like most members of Fabaceae family, is capable of forming symbioses with beneficial soil microorganisms such as nodule bacteria (rhizobia), arbuscular mycorrhizal (AM) fungi and plant growth promoting bacteria (PGPB). The autoregulation of nodulation (AON) system is known to play an important role in controlling both the number of nodules and the level of root colonization by AM via root-to-shoot signaling mediated by CLAVATA/ESR-related (CLE) peptides and their receptors. In the pea, mutations in genes Sym28 (CLV2-like) and Sym29 (CLV1-like), which encode receptors for CLE peptides, lead to the supernodulation phenotype, i.e., excessive nodule formation. The aim of the present study was to analyze the response of pea cv. ‘Frisson’ (wild type) and mutants P64 (sym28) and P88 (sym29) to complex inoculation with rhizobia, AM fungi and PGPB, with regard to biomass accumulation, yield and transcriptomic alterations. The plants were grown in quartz sand for 2 and 4 weeks after inoculation with either rhizobia (Rh) or complex inoculation with Rh + AM, Rh + PGPB, and Rh+AM+PGPB, and the biomass and yield were assessed. Transcriptome sequencing of whole shoots and roots was performed using a modified RNAseq protocol named MACE (Massive Analysis of cDNA Ends). In the experimental conditions, P88 (sym29) plants demonstrated the best biomass accumulation and yield, as compared to the wild type and P64 (sym28) plants, whereas P64 (sym28) had the lowest rate of biomass and seed yield. The transcriptome analysis showed that both supernodulating mutants more actively responded to biotic and abiotic factors than the wild-type plants and demonstrated increased expression of genes characteristic to late stages of nodule development. The roots of P64 (sym28) plants responded to AM+Rh treatment with upregulation of genes encoding plastid proteins, which can be connected with the activation of carotenoid biosynthesis (namely, the non-mevalonate pathway that takes place in root plastids). The more active response to symbionts in P88 (sym29) plants, as compared to cv. ‘Frisson’, was associated with counterregulation of transcripts involved in chloroplast functioning and development in leaves, which accompanies successful plant development in symbiotic conditions. Finally, the effect of retardation of plant aging upon mycorrhization on a transcriptomic level was recorded for cv. ‘Frisson’ but not for P64 (sym28) and P88 (sym29) mutants, which points towards its possible connection with the AON system. The results of this work link the plant’s autoregulation with the responsiveness to inoculation with beneficial soil microorganisms. RNAseq, transcriptomics, arbuscular mycorrhiza, nodule bacteria, complex inoculation, autoregulation of nodulation, garden pea
- 21 October 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (7-8) , 13-19
Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters
The activity of the antimetabolic drug Riamilovir (Triazavirin®) was studied on a model of SARS-CoV-2 infection on Syrian hamsters. Infectious process was caused by the intranasal administration of the virus accumulated in the Vero-B culture with a concentration of 4.25×104 TCID50, in a volume of 26 µl/hamster. The effects of the drug at a dose of 20 mg/kg intraperitoneally daily in the midst of the infectious process were traced to accelerate the clearance of the virus in the lungs, prevent body weight loss and the severity of pulmonary edema, as well as preserve the mass of the spleen. The protective effects of Riamilovir on the structure of the lungs and brain are shown, it is suggested that the drug has the ability to penetrate the blood-brain barrier. It was concluded that Riamilovir has antiviral activity against SARS-CoV-2.
- 21 October 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (7-8) , 13-19
Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters
The activity of the antimetabolic drug Riamilovir (Triazavirin®) was studied on a model of SARS-CoV-2 infection on Syrian hamsters. Infectious process was caused by the intranasal administration of the virus accumulated in the Vero-B culture with a concentration of 4.25×104 TCID50, in a volume of 26 µl/hamster. The effects of the drug at a dose of 20 mg/kg intraperitoneally daily in the midst of the infectious process were traced to accelerate the clearance of the virus in the lungs, prevent body weight loss and the severity of pulmonary edema, as well as preserve the mass of the spleen. The protective effects of Riamilovir on the structure of the lungs and brain are shown, it is suggested that the drug has the ability to penetrate the blood-brain barrier. It was concluded that Riamilovir has antiviral activity against SARS-CoV-2.
- Open Access
- 1 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (7) , 1624
Structural Variations in LysM Domains of LysM-RLK PsK1 May Result in a Different Effect on Pea–Rhizobial Symbiosis Development
Lysin-motif receptor-like kinase PsK1 is involved in symbiosis initiation and the maintenance of infection thread (IT) growth and bacterial release in pea. We verified PsK1 specificity in relation to the Nod factor structure using k1 and rhizobial mutants. Inoculation with nodO and nodE nodO mutants significantly reduced root hair deformations, curling, and the number of ITs in k1-1 and k1-2 mutants. These results indicated that PsK1 function may depend on Nod factor structures. PsK1 with replacement in kinase domain and PsSYM10 co-production in Nicotiana benthamiana leaves did not induce a hypersensitive response (HR) because of the impossibility of signal transduction into the cell. Replacement of P169S in LysM3 domain of PsK1 disturbed the extracellular domain (ECD) interaction with PsSYM10′s ECD in Y2H system and reduced HR during the co-production of full-length PsK1 and PsSYM0 in N. benthamiana. Lastly, we explored the role of PsK1 in symbiosis with arbuscular mycorrhizal (AM) fungi; no significant differences between wild-type plants and k1 mutants were found, suggesting a specific role of PsK1 in legume–rhizobial symbiosis. However, increased sensitivity to a highly aggressive Fusarium culmorum strain was found in k1 mutants compared with the wild type, which requires the further study of the role of PsK1 in immune response regulation.
- 1 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (7) , 1624
Open AccessStructural Variations in LysM Domains of LysM-RLK PsK1 May Result in a Different Effect on Pea–Rhizobial Symbiosis Development
Lysin-motif receptor-like kinase PsK1 is involved in symbiosis initiation and the maintenance of infection thread (IT) growth and bacterial release in pea. We verified PsK1 specificity in relation to the Nod factor structure using k1 and rhizobial mutants. Inoculation with nodO and nodE nodO mutants significantly reduced root hair deformations, curling, and the number of ITs in k1-1 and k1-2 mutants. These results indicated that PsK1 function may depend on Nod factor structures. PsK1 with replacement in kinase domain and PsSYM10 co-production in Nicotiana benthamiana leaves did not induce a hypersensitive response (HR) because of the impossibility of signal transduction into the cell. Replacement of P169S in LysM3 domain of PsK1 disturbed the extracellular domain (ECD) interaction with PsSYM10′s ECD in Y2H system and reduced HR during the co-production of full-length PsK1 and PsSYM0 in N. benthamiana. Lastly, we explored the role of PsK1 in symbiosis with arbuscular mycorrhizal (AM) fungi; no significant differences between wild-type plants and k1 mutants were found, suggesting a specific role of PsK1 in legume–rhizobial symbiosis. However, increased sensitivity to a highly aggressive Fusarium culmorum strain was found in k1 mutants compared with the wild type, which requires the further study of the role of PsK1 in immune response regulation.
- Open Access
- 25 December 2017
- Published by ECO-Vector LLC in Ecological genetics
- Vol. 15 (4) , 4-12
Studying the biochemical function of the pea receptor-like kinases sym10, sym37 and k1, required for the legume-rhizobia symbiosis development
Background. Rhizobial Nod factors (NFs), the key regulators of legume-rhizobia symbiosis, act in low concentrations and their biological activity depends on structural features, that suggests the presence of specific receptors in plants. Putative receptors, LysM-receptor-like kinases (LysM-RLKs), were found in model legumes L. japonicus and M. truncatula. However, binding capacity with NFs was only studied for L. japonicus LysM-RLKs. In pea a few candidates for NF receptors like Sym10, Sym37 and K1 were found. Analysis of mutants revealed the importance of these proteins for symbiosis development. However, the biochemical function of these receptors has not been studied. Materials and methods. Sequences encoding extracellular domains (ECDs) of LysM-RLKs Sym10, Sym37, and K1 were cloned in the pRSETa vector. Constructs were introduced in E. coli strain C41 to produce proteins with His6 residues on either the amino or carboxyl terminus. Protein purification was carried out using metal chelate affinity chromatography. The binding capacity with ligand was evaluated using ProteonXPR36 biosensor. Results. To study binding capacity with NFs, we have developed approaches for the synthesis of LysM-RLK Sym10, Sym37 and K1 in soluble form in heterologous system. The high level of protein synthesis was achieved at +28 C using 0,5 mM IPTG in 2-16 hours. Analysis of binding capacity of ECDs with NFs revealed the low affinity using the surface plasmon resonance. Conclusion. The possibility of recombinant receptor synthesis in soluble state in E. coli at high level was demonstrated. Analysis of binding capacity with NFs showed the potential interaction, but with low affinity.
- 25 December 2017
- Published by ECO-Vector LLC in Ecological genetics
- Vol. 15 (4) , 4-12
Open AccessStudying the biochemical function of the pea receptor-like kinases sym10, sym37 and k1, required for the legume-rhizobia symbiosis development
Background. Rhizobial Nod factors (NFs), the key regulators of legume-rhizobia symbiosis, act in low concentrations and their biological activity depends on structural features, that suggests the presence of specific receptors in plants. Putative receptors, LysM-receptor-like kinases (LysM-RLKs), were found in model legumes L. japonicus and M. truncatula. However, binding capacity with NFs was only studied for L. japonicus LysM-RLKs. In pea a few candidates for NF receptors like Sym10, Sym37 and K1 were found. Analysis of mutants revealed the importance of these proteins for symbiosis development. However, the biochemical function of these receptors has not been studied. Materials and methods. Sequences encoding extracellular domains (ECDs) of LysM-RLKs Sym10, Sym37, and K1 were cloned in the pRSETa vector. Constructs were introduced in E. coli strain C41 to produce proteins with His6 residues on either the amino or carboxyl terminus. Protein purification was carried out using metal chelate affinity chromatography. The binding capacity with ligand was evaluated using ProteonXPR36 biosensor. Results. To study binding capacity with NFs, we have developed approaches for the synthesis of LysM-RLK Sym10, Sym37 and K1 in soluble form in heterologous system. The high level of protein synthesis was achieved at +28 C using 0,5 mM IPTG in 2-16 hours. Analysis of binding capacity of ECDs with NFs revealed the low affinity using the surface plasmon resonance. Conclusion. The possibility of recombinant receptor synthesis in soluble state in E. coli at high level was demonstrated. Analysis of binding capacity with NFs showed the potential interaction, but with low affinity.